clinical trial · NCT02483936
Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control
EMS·phase3·withdrawn
Arterial HypertensionOlmesartan medoxomil 40mg + chlorthalidone 12,5mgOlmesartan medoxomil 40mg + chlorthalidone 25mgOlmesartan 40mg + Hydrochlorothiazide 12,5mgOlmesartan 40mg + Hydrochlorothiazide 25mg
brief summary
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
started
—
primary completion
Jun 1, 2025
completion
—
last updated
Dec 8, 2025
official title
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan Medoxomil + Chlorthalidone (40mg + 12.5mg and 40mg + 25mg) Compared With BENICAR HCT® in Hypertension Control
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol